BCL2L1 and cancer: NF-κB signaling via expression regulation of multiple target genes (e.g., BCLXL, BCL2, BCLXS, TNF-α, IL6, XIAP, and VEGF) represents an essential cellular pathway that is extensively involved in acquired therapy resistance in cancer [5].